Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1736 participants.

Also called NCT01864174

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,736 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01864174
  • EudraCT 2012-004531-23
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Germany, Hungary, Poland, Puerto Rico, Romania, South Africa, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01864174. Randomized; double masking; primary purpose treatment. Start 2013-06-20 (actual); primary completion 2016-06-01 (actual). Results posted on 2017-07-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Metformin XR
Intervention (Drug)
Metformin IR
Intervention (Drug)
Placebo matching with Metformin XR
Intervention (Drug)
Placebo matching with Metformin IR
Lead sponsor
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct01864174
Content hash
39db22bad55397f8890af2ec483d19df5926a58966dfe9335661e0ef85ecd790